Eli Lilly reports positive results from phase III CENTURION study of lasmiditan (Reyvow) for migraine attacks

RCT (n=1471) of this ditan which penetrates CNS and selectively targets 5‑HT1F receptors in trigeminal nerve pathway showed those on 200mg had 4.6 times greater odds of achieving pain freedom at 2 hours vs placebo, with therapeutic gain of ~21% (3.8 times and 17% for 100mg dose).


Biospace Inc.